AdAlta Ltd
1AD
Company Profile
Business description
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation cells and protein based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
Contact
697 Burke Road
Suite 201
CamberwellVIC3124
AUST: +61 394795159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,966.50 | 92.30 | -1.02% |
| CAC 40 | 8,238.17 | 23.99 | -0.29% |
| DAX 40 | 24,491.06 | 111.98 | -0.46% |
| Dow JONES (US) | 49,053.22 | 448.08 | -0.91% |
| FTSE 100 | 10,309.22 | 93.12 | -0.90% |
| HKSE | 26,555.93 | 329.31 | -1.22% |
| NASDAQ | 22,667.53 | 237.05 | -1.03% |
| Nikkei 225 | 54,073.52 | 255.48 | 0.47% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,821.72 | 61.00 | -0.89% |
| S&P/ASX 200 | 8,718.70 | 86.80 | -0.99% |
| SSE Composite Index | 4,080.23 | 4.31 | 0.11% |